Close Menu

lawsuit

The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.

The complaint, filed yesterday, alleges that Illumina's two-channel sequencing systems infringe Complete Genomics' US Patent No. 9,222,132.

PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.

The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.

The plaintiffs are concerned by the growth of DNA databases for law enforcement and want the government to automatically delete profiles of people not convicted of felonies.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

Pages

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.